London, Feb 24, 2026, 08:15 GMT — Regular session
- GSK shares slipped roughly 1% at the open in London.
- The company announced new share buybacks as part of its ongoing programme.
- Bora Pharmaceuticals has landed a fresh $250 million manufacturing contract with GSK, the company announced.
GSK slipped 1.1% to 2,182 pence in early London hours Tuesday, as the company unveiled new buybacks and news broke of a fresh manufacturing deal with Bora Pharmaceuticals.
The steady pace of buybacks has real impact here—a rare tool for management to shore up earnings per share when there’s not much else in the news. As for the Bora contract, it shifts the spotlight again to supply chain durability and the decisions major pharma names are making about production sites for older drugs.
GSK disclosed it picked up 462,000 shares on Monday, paying a volume-weighted average of 2,200.95 pence per share. The company plans to keep these in treasury. Since Feb. 17, the total tally has reached 2.229 million shares, according to GSK. Treasury shares, as usual, don’t come with voting rights.
On the previous day, GSK disclosed snapping up 467,000 shares on Feb. 20, paying an average of 2,223.53 pence each. That latest buy pushed total repurchases since Feb. 17 to 1.767 million shares.
Bora on Monday announced it’s landed a fresh five-year, $250 million global manufacturing deal with GSK, extending a relationship that began when Bora acquired GSK’s Mississauga, Canada site in 2020. “Strong partnerships like this are foundational to the continued growth of Bora’s CDMO business,” said J.D. Mowery, who heads Bora’s contract manufacturing arm. Bora Corp
Bora says the deal spans manufacturing for over 20 commercial product lines and upwards of 335 products, with GSK also gaining access to Bora’s oral solid-dose facility in Maple Grove, Minnesota. CEO Bobby Sheng described the agreement, which he says is “committing through 2030,” as a sign of focus on “value and reliability.” Fiercepharma
This isn’t a growth story for investors. It comes down to execution—making sure the existing drugs keep moving and the risk of expensive supply hiccups stays low, as big pharma pours resources into new product launches.
Still, there’s a risk here. If cash generation falls short, buybacks could lose momentum. And contract manufacturing isn’t immune—operational or compliance trouble at a facility, or a squeeze on capacity, can cause headaches.
Stock traders are watching how quickly repurchases come through over the next few sessions—and if the ongoing program manages to keep shares stable as it chips away at the free float.
GSK will report its first-quarter figures on April 29.
